Search results for "vascular endothelial growth factor"

showing 10 items of 320 documents

Host immunogenetics and control of human herpesvirus-8 infection

2006

BACKGROUND: Kaposi sarcoma (KS) is primarily caused by human herpesvirus (HHV)-8 infection, and the risk is increased with high HHV-8 lytic or latent antibody titers or the detection of HHV-8 DNA in peripheral blood mononuclear cells (PBMCs). Host genes important for control of HHV-8 infection are not well characterized. METHODS: In 172 HHV-8 latent nuclear antigen (LANA)-seropositive adults in Italy without KS, we examined correlations of common variants in host immune genes with the detection of HHV-8 DNA in PBMCs and with high lytic and latent antibody titers. Twenty-eight single-nucleotide polymorphisms in 14 genes were analyzed. We detected HHV-8 DNA in PBMCs with real-time amplificati…

AdultMaleVascular Endothelial Growth Factor ASimplexvirusfood.ingredientvirusesImmunogeneticsBiologymedicine.disease_causeAntibodies ViralHerpesviridaefoodAntigenLatent Nuclear AntigenRisk FactorsImmunogeneticsmedicineImmunology and AllergyHumansAgedAntibody titervirus diseasesHerpesviridae Infectionsbiochemical phenomena metabolism and nutritionMiddle AgedVirologyEditorial CommentaryTiterInfectious DiseasesLytic cycleHaplotypesImmunologyDNA ViralHerpesvirus 8 HumanLeukocytes MononuclearCytokinesFemale
researchProduct

Vascular endothelial growth factor gene polymorphisms in Behçet's disease

2004

Objective. To evaluate potential associations of vascular endothelial growth factor (VEGF) gene polymorphisms with Behçet's disease (BD) and disease expression. Methods. Case patients were 122 consecutive Italian patients with BD followed at the Rheumatology, Ophthalmology, and Neurology Units in Bologna, Ferrara, Milano, Palermo, Potenza, Prato, Reggio Emilia, and Trento over a 3-year period (1997-99) and who satisfied the International Study Group criteria for BD. Also selected as a control group were 200 healthy age and sex matched blood donors. All patients with BD and controls were genotyped by polymerase chain reaction and allele-specific oligonucleotide techniques for +936 C/T (rs302…

AdultMaleVascular Endothelial Growth Factor Aclinical manifestationsPolymorphism GeneticAdolescentGenotypeBehcet SyndromeVEGF productionBehcet's diseaseVEGF polymorphismGene FrequencyLeukocytes MononuclearHumansAdolescent; Adult; Behcet Syndrome; Cells Cultured; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Leukocytes Mononuclear; Male; Vascular Endothelial Growth Factor A; Polymorphism GeneticFemaleGenetic Predisposition to DiseaseCells Cultured
researchProduct

Serum VEGF and b-FGF profiles after tension-free or conventional hernioplasty.

2005

Angiogenesis is strongly influenced by vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF), whose production is also regulated by interferon (IFN)-gamma and interleukin (IL)-10. The aim of this study was to evaluate the modifications of serum VEGF, b-FGF, IFN-gamma and IL-10 levels in patients with inguinal hernia undergoing hernioplasty with the Lichtenstein technique (LH) using polypropylene mesh or with Bassini open conventional inguinal hernia repair (BH). MATERIALS AND METHODS: Randomly, 16 patients underwent BH, and 16 were treated with the LH technique using polypropylene mesh. Blood samples were collected 24 h prior to surgery and then 6, 24, 48 and …

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisBasic fibroblast growth factorUrologyEnzyme-Linked Immunosorbent AssayHernia InguinalStatistics Nonparametricchemistry.chemical_compoundInterferon-gammaMedicineHumansIFN-γMeshAnalysis of Variancebusiness.industryInterleukinMiddle AgedSurgical Meshmedicine.diseaseVEGFSurgeryInterleukin-10Vascular endothelial growth factorInterleukin 10Inguinal herniachemistryHernioplastyIL-10SurgeryCytokine secretionFibroblast Growth Factor 2b-FGFbusinessAbdominal surgery
researchProduct

Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients

2006

INTRODUCTION Angiogenesis has been correlated with increased invasion and metastases in a variety of human neoplasms. Inadequate inhibition of the growth of tumor microvessels by anticancer agents may result in treatment failure, rated clinically as progressive or stable disease. We designed this trial to investigate the modification of the vascular endothelial growth factor (VEGF) and interferon-gamma (IFN-gamma) in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. MATERIALS AND METHODS Forty-five metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF and IFN-gamma during the treatment wit…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisColorectal cancerCetuximabAntibodies Monoclonal HumanizedIrinotecanGastroenterologyNeovascularizationInterferon-gammaBasal (phylogenetics)chemistry.chemical_compoundangiogenesis cetuximab colorectal cancer irinotecanInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyAgedNeovascularization PathologicCetuximabbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseVascular endothelial growth factorIrinotecanTreatment OutcomeEndocrinologyOncologychemistryCamptothecinFemalemedicine.symptomColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Induction of vascular endothelial growth factor release by transcutaneous frequency modulated neural stimulation in diabetic polyneuropathy

2008

Background: Pharmacological treatment for diabetic polyneuropathy (DP) has shown limited benefit; frequency-modulated electrical stimulation (FREMS) has shown positive results in pain control and nerve conduction velocity in DP. Objective: To investigate the effects of FREMS vs transcutaneous electrical nerve stimulation (TENS) on the release of vascular endothelial growth factor (VEGF) in Type 2 diabetic and in non-diabetic subjects. Methods: 10 non-diabetic [mean age 37±5 yr; females (F)/males (M): 6/4] and 10 Type 2 diabetic subjects (mean age 52±6 yr; F/M: 5/5) with DP underwent TENS (for 10 min) followed by 30 min interval without electrical stimulation, and then FREMS (for 10 min) ove…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyDiabetic neuropathyEndocrinology Diabetes and MetabolismNeural ConductionAction PotentialsPainElectric Stimulation TherapyStimulationTranscutaneous electrical nerve stimulationNerve conduction velocitylaw.inventionchemistry.chemical_compoundEndocrinologyDiabetic NeuropathiesForearmlawInternal medicineVasa nervorumHumansPain ManagementMedicineMotor Neuronsbusiness.industryMicroangiopathyMiddle Agedmedicine.diseaseVascular endothelial growth factorEndocrinologymedicine.anatomical_structurechemistryTranscutaneous Electric Nerve StimulationFemalebusiness
researchProduct

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial

2014

Purpose To compare standard-of-care grid laser photocoagulation versus intravitreal ranibizumab (IVR) versus a combination of both in the treatment of chronic (>3 months) macular oedema secondary to branch retinal vein occlusion. Methods Prospective, randomized, multicentre clinical trial. Thirty patients with a best-corrected visual acuity (BCVA) between 20/320 and 20/40 were randomized 1:1:1 to receive grid laser or three monthly injections of 0.5 mg IVR or both followed by 3 months of observation. Results Mean change from baseline BCVA at month 6 was +2 letters [laser; 0.04 logMAR, 95% confidence interval (−0.17; 0.25)], +17 letters [IVR; 0.34 (0.19; 0.5)] and +6 letters [combination; 0.…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular Edemalaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialRecurrencelawRanibizumabOphthalmologyRetinal Vein OcclusionHumansMedicineProspective Studies030212 general & internal medicineMacular edemaAgedAged 80 and overLaser Coagulationbusiness.industryRetinalGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyConfidence interval3. Good healthSurgeryClinical trialOphthalmologychemistryIntravitreal Injections030221 ophthalmology & optometryBranch retinal vein occlusionFemaleLasers SemiconductorRanibizumabmedicine.symptombusinessmedicine.drugActa Ophthalmologica
researchProduct

Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflamma…

2013

Maria D Pinazo-Durán,1,* Carmen Galbis-Estrada,1,* Sheila Pons-Vázquez,1 Jorge Cantú-Dibildox,2 Carla Marco-Ramírez,1 Javier Benítez-del-Castillo21Ophthalmic Research Unit Santiago Grisolia, Department of Surgery/Ophthalmology, Faculty of Medicine, University of Valencia, Valencia, Spain; 2Department of Ophthalmology, Hospital of Jerez, Jerez de la Frontera, Spain*These authors contributed equally to this workBackground: Women, and those older than 65 years of age, are particularly susceptible to dry eye disorders (DEDs). Inflammation is clearly involved in the pathogenesis of DEDs, and there is mounting evidence on the antioxidant and …

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyessential polyunsaturated fatty acidsInterleukin-1betaInflammationnutraceuticsGastroenterologyAntioxidantsPathogenesischemistry.chemical_compoundRisk FactorsInternal medicineFatty Acids Omega-3HumansMedicineProspective StudiesInterleukin 6Prospective cohort studyAgedOriginal ResearchAged 80 and overchemistry.chemical_classificationbiologyInterleukin-6business.industryagingtearsInterleukinGeneral MedicineMiddle AgedcytokinesInterleukin-10Vascular endothelial growth factorchemistryClinical Interventions in AgingDietary SupplementsImmunologybiology.proteinTearsDry Eye SyndromesFemalewomenInflammation MediatorsGeriatrics and Gerontologymedicine.symptombusinessPolyunsaturated fatty acidClinical Interventions in Aging
researchProduct

Aqueous Humor Levels of Vascular Endothelial Growth Factor in Retinitis Pigmentosa

2008

PURPOSE To determine the level of vascular endothelial growth factor A (VEGF-A) in aqueous humors of patients with retinitis pigmentosa (RP). METHODS A prospective, comparative control study. Aqueous humor was collected from 16 eyes of 16 patients with RP. The level of VEGF-A was determined with a commercially available enzyme-linked immunosorbent assay kit. The control group comprised 16 aqueous samples from 16 patients about to undergo cataract surgery and without any other ocular or systemic diseases. RESULTS The concentration of VEGF-A in aqueous humor was markedly lower in patients with RP than in control subjects (Mann-Whitney U test, P < 0.001). The level of VEGF-A was 94.9 +/- 99.8 …

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentEye diseaseEnzyme-Linked Immunosorbent AssayAqueous humorAqueous Humorchemistry.chemical_compoundOphthalmologyRetinitis pigmentosaHumansMedicineProspective StudiesAgedbusiness.industryMiddle AgedCataract surgerymedicine.diseaseControl subjectseye diseasesVascular endothelial growth factorVascular endothelial growth factor AchemistryFemalesense organsbusinessRetinitis PigmentosaRetinopathyInvestigative Opthalmology &amp; Visual Science
researchProduct

Elevated protein carbonyl and HIF-1α levels in eyes with proliferative diabetic retinopathy.

2013

Purpose: To evaluate the role of protein carbonyls and hypoxia inducible factor-1a (HIF-1a) in diabetic eyes with proliferative diabetic retinopathy (PDR). Methods: Prospective consecutive controlled observational study was performed. Vitreous samples were collected at the start of the 3-ppp vitrectomy. Protein carbonylation analysis was performed by Western blotting with antibody against 2,4-Dinitrophenol (anti-DNP), following derivatization of protein carbonyls with 2,4 Dinitrophenylhydrazine (DNHP). Protein carbonylation was quantified by scanning densitometry analysis and relativized to the total amount of protein into the ponceau staining of membranes. Vitreous HIF-1 a was determined w…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentProtein CarbonylationBlotting WesternVitrectomyEnzyme-Linked Immunosorbent Assaymedicine.disease_causePathogenesisProtein Carbonylationchemistry.chemical_compoundOphthalmologyVitrectomymedicineHumansProspective StudiesMacular holeAgedGlycated HemoglobinDiabetic Retinopathybusiness.industryRetinal detachmentGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseHypoxia-Inducible Factor 1 alpha Subuniteye diseasesSurgeryVascular endothelial growth factorVitreous BodyOphthalmologyOxidative StressDiabetes Mellitus Type 1chemistryDiabetes Mellitus Type 2Femalesense organsbusinessOxidative stressActa ophthalmologica
researchProduct

Impact of Heavy Polypropylene Mesh and Composite Light Polypropylene and Polyglactin 910 on the Inflammatory Response

2010

The aim of the study was to analyze the acute inflammatory response after implantation of a heavyweight mesh of polypropylene (PP) compared with a composite mesh of light PP and polyglactin 910 (PG) in patients undergoing inguinal hernioplasty. A total of 30 male patients with inguinal hernia were included in the study and divided into 2 groups (PP and PP-PG) according to the mesh used. Changes of leukocytes, cytokines, growth factors, and acute phase proteins were evaluated in the sera. Leukocytes and acute phase proteins were significantly increased postoperatively in both groups, and the values were slightly higher in the PP group. Cytokine levels were significantly increased postoperat…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtymedicine.medical_treatmentInflammatory responseUrologyBiocompatible MaterialsHernia InguinalPolypropylenesProinflammatory cytokinechemistry.chemical_compoundTransforming Growth Factor betaHumansMedicineHerniaPolyglactin 910AgedInflammationPolypropyleneInterleukin-6business.industryPolyglactin 910Acute-phase proteinMiddle AgedSurgical Meshmedicine.diseaseSurgeryFibroblast Growth FactorsInterleukin 1 Receptor Antagonist ProteinInguinal herniaC-Reactive ProteinCytokinechemistrySurgerybusinessSurgical Innovation
researchProduct